Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Change in Acquisitions & Divestments: 2018-2025

Historic Change in Acquisitions & Divestments for UroGen Pharma (URGN) over the last 6 years, with Sep 2025 value amounting to $40.2 million.

  • UroGen Pharma's Change in Acquisitions & Divestments rose 231.19% to $40.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $180.9 million, marking a year-over-year increase of 338.37%. This contributed to the annual value of $107.7 million for FY2024, which is 119.48% up from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Change in Acquisitions & Divestments is $40.2 million, which was up 32.54% from $30.3 million recorded in Q2 2025.
  • UroGen Pharma's 5-year Change in Acquisitions & Divestments high stood at $70.0 million for Q4 2024, and its period low was -$88,000 during Q2 2022.
  • Moreover, its 3-year median value for Change in Acquisitions & Divestments was $13.5 million (2024), whereas its average is $24.3 million.
  • As far as peak fluctuations go, UroGen Pharma's Change in Acquisitions & Divestments tumbled by 100.80% in 2022, and later surged by 4,344.32% in 2023.
  • UroGen Pharma's Change in Acquisitions & Divestments (Quarterly) stood at $9.6 million in 2021, then surged by 140.07% to $23.1 million in 2022, then tumbled by 84.71% to $3.5 million in 2023, then surged by 1,879.21% to $70.0 million in 2024, then surged by 231.19% to $40.2 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $40.2 million for Q3 2025, versus $30.3 million for Q2 2025 and $40.4 million for Q1 2025.